Merck & Co., Inc. (NYSE:MRK)

CAPS Rating: 4 out of 5

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health.


Player Avatar TMFCane (< 20) Submitted: 12/17/2012 3:16:16 AM : Outperform Start Price: $43.21 MRK Score: -4.16

Januvia and Janumet are poised to explode with the diabetes market. Suvorexant and odanacatib both look good, and keeping all its divisions together (rather than spinning them off a la Abbott and Pfizer) should allow Merck to capitalize on growth segments. This company's done well in compensating for Singulair's loss.

Featured Broker Partners